As of 6 Nov 2026, Rubicon Research trades at 95.6× trailing earnings, above the industry P/E of 37.3×, and the shares are 13% below their 52-week high. It earns ROCE of 24% and ROE of 31%. Its dividend yield is 0.1%, and debt is 0.35× equity. It is a small-cap company with a market cap of ₹27,468 Cr, ranked 2nd of 15 Drug Manufacturers (General) companies by market cap; the shares rose 167% over the past year.
- ₹1,769.00
- ₹1,769.00
- ₹1,606.00
- ₹1,740.60
- 6.9 L
Health check
- ReturnsAhead
+166.7% over a year, better than 7 of 7 peers.
- Price tagPricier
P/E 95.6 vs industry 37.3.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityStrong
ROCE 23.6% vs peer median 22.9%.
- Balance sheetSolid
Debt 0.35× equity, interest covered 11.3×.
- Red flags1 to check
P/E of 95.6 against an industry P/E of 37.3.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹27,468 Cr
- Small cap
- P/E
- 95.6
- Industry 37.3
- Price to book
- 19.38
- Peers 9.15
- Dividend yield
- 0.09%
- ROE
- 31.3%
- Peers 28.3%
- ROCE
- 23.6%
- Peers 22.9%
- Debt to equity
- 0.35
- Debt ₹501 Cr
- EPS (TTM)
- ₹17.36
- Face value ₹1
- OPM (TTM)
- 23.3%
- Net margin 15.5%
- Sales growth
- +51.6%
- Latest quarter vs a year ago
- Profit growth
- +55.9%
- Latest quarter vs a year ago
- Price to sales
- 13.08
- EV/EBITDA 57.2
Strengths and risks
Strengths
- Return on equity of 31.3%.
- Return on capital employed of 23.6%.
- Quarterly profit up 55.9% on a year ago.
- Quarterly sales up 51.6% on a year ago.
Risks to check
- P/E of 95.6 against an industry P/E of 37.3.
About Rubicon Research
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a…
- Headquarters
- Mumbai
- Employees
- 1,290
- Sector
- Healthcare
- ISIN
- INE506V01022
- Website
- rubicon.co.in
Price range
- Avg volume (3M)
- 3.2 L
- 1-year return
- plus 166.7%
- From 52-week high
- minus 12.6%
Peers · Drug Manufacturers - General
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLAXOGlaxosmithkline Pharmaceuticals | 2,524.80 | plus 0.98% | 42,772 | 37.3 | 22.73 | 55.4% | 63.9% | 34.1% | 5.7% | 19.3% | 2.26% | minus 6.0% |
| RUBICONRubicon Research | 1,659.30 | minus 4.67% | 27,468 | 95.6 | 19.38 | 23.6% | 19.1% | 23.3% | – | – | 0.09% | plus 166.7% |
| PFIZERPfizer | 3,856.00 | minus 0.02% | 17,640 | 23.2 | 4.02 | 22.9% | 20.9% | 36.7% | 1.3% | 5.0% | 1.94% | minus 24.6% |
| CORONACORONA Remedies | 2,441.10 | plus 2.58% | 14,930 | 72.1 | 18.55 | 29.0% | 28.3% | 21.3% | 16.6% | 29.7% | 0.41% | plus 69.7% |
| MARKSANSMarksans Pharma | 303.70 | minus 3.20% | 13,764 | 24.6 | 4.13 | 17.5% | 15.2% | 22.5% | 16.7% | 16.2% | 0.30% | plus 68.0% |
| SYMBIOTECSymbiotec Pharmalab | 1,513.60 | plus 19.04% | 9,726 | 103.5 | 8.26 | 14.3% | 11.2% | 10.7% | 16.8% | 67.3% | 0.00% | plus 37.9% |
| SANOFICONRSanofi Consumer Healthcare India | 3,420.20 | minus 0.69% | 7,888 | 28.2 | 22.64 | – | 80.4% | 37.8% | – | – | 2.19% | minus 29.5% |
| SANOFISanofi India | 3,283.10 | minus 2.75% | 7,561 | 20.7 | 9.15 | – | 44.1% | 28.0% | – | – | 3.75% | minus 28.9% |
| Median of 7 peers | – | −0.02% | 13,764 | 28.2 | 9.15 | 22.9% | 28.3% | 28.0% | 16.6% | 19.3% | 1.94% | −6.0% |
Quarterly results
| ₹ Cr | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|
| – | 352 | 412 | 476 | 514 | 534 | |
| – | 283 | 318 | 367 | 395 | 405 | |
| – | 69.5 | 94.3 | 108 | 119 | 129 | |
| – | 19.7% | 22.9% | 22.7% | 23.1% | 24.2% | |
| – | – | 0.7 | 3.8 | 2.6 | 5.7 | |
| – | 10.6 | 11.4 | 9.8 | 10.4 | 9.3 | |
| 9.7 | – | 11.9 | 11.6 | 12.3 | 15.1 | |
| 51.1 | – | 71.7 | 90.6 | 98.7 | 110 | |
| 29.0% | – | 24.9% | 19.6% | 22.2% | 23.2% | |
| 36.2 | – | 53.9 | 72.8 | 76.8 | 84.8 | |
| 2.20 | – | 3.27 | 4.41 | 4.60 | 5.08 |
Profit & loss
- ROE
- 31.3%
| ₹ Cr | Mar 2025 | Mar 2026 |
|---|---|---|
| 1,267 | 1,731 | |
| 1,047 | 1,330 | |
| 220 | 401 | |
| 17.3% | 23.2% | |
| – | −2.5 | |
| 34.7 | 31.1 | |
| – | 45.3 | |
| 0.6 | −2 | |
| – | 321 | |
| – | 23.0% | |
| – | 247 | |
| – | 15.31 |
Forecast
Balance sheet
| ₹ Cr | Mar 2026 |
|---|---|
| 16.5 | |
| 1,272 | |
| 311 | |
| 727 | |
| 2,327 | |
| 519 | |
| 51.3 | |
| 26.6 | |
| 336 | |
| 1,394 | |
| 2,327 |
Cash flow
| ₹ Cr | Mar 2026 |
|---|---|
| 205 | |
| −410 | |
| 283 | |
| 78.4 | |
| −229 | |
| −24.1 | |
| −0.3 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 18.2% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.